Pub Date : 2025-09-04DOI: 10.3389/fsci.2025.1514835
Mark Blaxter, Harris A Lewin, Federica DiPalma, Richard Challis, Manuela da Silva, Richard Durbin, Giulio Formenti, Nico Franz, Roderic Guigo, Peter W Harrison, Michael Hiller, Katharina J Hoff, Kerstin Howe, Erich D Jarvis, Mara K N Lawniczak, Kerstin Lindblad-Toh, Debra J H Mathews, Fergal J Martin, Camila J Mazzoni, Ann M McCartney, Nicola Mulder, Sadye Paez, Kim D Pruitt, Verena Ras, Oliver A Ryder, Lesley Shirley, Franç Oise Thibaud-Nissen, Tandy Warnow, Robert M Waterhouse
<p><p>The Earth BioGenome Project (EBP) aims to "sequence life for the future of life" by generating high-quality reference genome sequences for all recognized eukaryotic species, thereby building a rich knowledge base to inform conservation, inspire bioindustry, ensure food security, advance medicine, and establish a deeper understanding of biodiversity. As the EBP works toward completing the original Phase I goal-a reference genome for each of the approximately 10,000 taxonomic families of eukaryotes-milestone publications have demonstrated the transformative potential of the project. The EBP has promoted global collaboration and established core methods and standards. By the end of 2024, EBP-affiliated projects had publicly released 2,000 high-quality genome assemblies, representing more than 500 eukaryotic families. In this article, we present a revised set of goals for Phases I and II of the EBP. For Phase II, we propose generating reference genomes for 150,000 species over 4 years, including representative genomes for at least 50% of all accepted genera and for additional species of biological and economic importance. To deliver Phase II, EBP-affiliated projects will have to release over 3,000 new genomes per month. We review the magnitude of the tasks in sourcing, sequencing, assembling, annotating, and analyzing genomes at this scale, and explore the scientific, technical, social, legal, ethical, and funding challenges associated with them. Success in Phase II will set the stage for sequencing the remaining ~1.5 million named species of Eukaryota and establishing the knowledge platforms necessary for understanding, preserving, and utilizing Earth's biodiversity in an era of rapid environmental change.</p><p><strong>Key points: </strong>The ongoing success of Phase I of the Earth Biogenome Project (EBP) demonstrates the feasibility of producing reference-quality genomes at scale, enabling the project to achieve its overarching goal: to sequence 1.67 million eukaryotic species in 10 years.Using knowledge from Phase I projects, we propose a revised strategy for Phase II: collecting specimens for 300,000 species and sequencing 150,000 species, representing at least half of the eukaryotic genera, in 4 years.Technical advances in DNA sequencing, genome assembly, and genome annotation have reduced costs and increased throughput to the point that we envisage globally distributed production of reference-quality genomes for most eukaryotic species for a total cost of about US$3.9 billion-US$800 million less than initially envisioned.Key challenges remain, including enhancing global coordination and building communities of users and interested parties; creating an inclusive, global biodiversity genomics workforce; developing effective access and benefit-sharing methodologies; facilitating collection at scale of vouchered specimens; sequencing reference genomes from single-celled and very small organisms; enhancing functional annotation; and building
{"title":"The Earth BioGenome Project Phase II: illuminating the eukaryotic tree of life.","authors":"Mark Blaxter, Harris A Lewin, Federica DiPalma, Richard Challis, Manuela da Silva, Richard Durbin, Giulio Formenti, Nico Franz, Roderic Guigo, Peter W Harrison, Michael Hiller, Katharina J Hoff, Kerstin Howe, Erich D Jarvis, Mara K N Lawniczak, Kerstin Lindblad-Toh, Debra J H Mathews, Fergal J Martin, Camila J Mazzoni, Ann M McCartney, Nicola Mulder, Sadye Paez, Kim D Pruitt, Verena Ras, Oliver A Ryder, Lesley Shirley, Franç Oise Thibaud-Nissen, Tandy Warnow, Robert M Waterhouse","doi":"10.3389/fsci.2025.1514835","DOIUrl":"10.3389/fsci.2025.1514835","url":null,"abstract":"<p><p>The Earth BioGenome Project (EBP) aims to \"sequence life for the future of life\" by generating high-quality reference genome sequences for all recognized eukaryotic species, thereby building a rich knowledge base to inform conservation, inspire bioindustry, ensure food security, advance medicine, and establish a deeper understanding of biodiversity. As the EBP works toward completing the original Phase I goal-a reference genome for each of the approximately 10,000 taxonomic families of eukaryotes-milestone publications have demonstrated the transformative potential of the project. The EBP has promoted global collaboration and established core methods and standards. By the end of 2024, EBP-affiliated projects had publicly released 2,000 high-quality genome assemblies, representing more than 500 eukaryotic families. In this article, we present a revised set of goals for Phases I and II of the EBP. For Phase II, we propose generating reference genomes for 150,000 species over 4 years, including representative genomes for at least 50% of all accepted genera and for additional species of biological and economic importance. To deliver Phase II, EBP-affiliated projects will have to release over 3,000 new genomes per month. We review the magnitude of the tasks in sourcing, sequencing, assembling, annotating, and analyzing genomes at this scale, and explore the scientific, technical, social, legal, ethical, and funding challenges associated with them. Success in Phase II will set the stage for sequencing the remaining ~1.5 million named species of Eukaryota and establishing the knowledge platforms necessary for understanding, preserving, and utilizing Earth's biodiversity in an era of rapid environmental change.</p><p><strong>Key points: </strong>The ongoing success of Phase I of the Earth Biogenome Project (EBP) demonstrates the feasibility of producing reference-quality genomes at scale, enabling the project to achieve its overarching goal: to sequence 1.67 million eukaryotic species in 10 years.Using knowledge from Phase I projects, we propose a revised strategy for Phase II: collecting specimens for 300,000 species and sequencing 150,000 species, representing at least half of the eukaryotic genera, in 4 years.Technical advances in DNA sequencing, genome assembly, and genome annotation have reduced costs and increased throughput to the point that we envisage globally distributed production of reference-quality genomes for most eukaryotic species for a total cost of about US$3.9 billion-US$800 million less than initially envisioned.Key challenges remain, including enhancing global coordination and building communities of users and interested parties; creating an inclusive, global biodiversity genomics workforce; developing effective access and benefit-sharing methodologies; facilitating collection at scale of vouchered specimens; sequencing reference genomes from single-celled and very small organisms; enhancing functional annotation; and building","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7618684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-10-07DOI: 10.3389/fsci.2025.1474469
Masanori Aikawa, Abhijeet R Sonawane, Sarvesh Chelvanambi, Takaharu Asano, Arda Halu, Joan T Matamalas, Sasha A Singh, Shizuka Uchida, Elena Aikawa, Alex Arenas, Jean-Luc Balligand, Chiara Giannarelli, Calum A MacRae, Neil V Morgan, Cécile Oury, Hendrik Tevaearai Stahel, Joseph Loscalzo
Despite the development of potent drugs for modifiable risk factors and advances in mechanistic biomedical research, cardiovascular diseases (CVDs) collectively remain the leading cause of death globally, indicating a need for new, more effective therapies. A foundational challenge is the multilevel heterogeneity that characterizes CVDs-from their complex pathobiological mechanisms at the molecular and cellular levels, to their clinical presentations and therapeutic responses at the individual and population levels. This variability arises from individuals' unique genomic and exposomic characteristics, underscoring the need for precision approaches. Other key challenges include the long navigation times, high costs, and low success rates for drug development, often compounded by the poor "druggability" of new targets. In this article, we explore how these challenges have inspired novel technologies that offer promise in improving health outcomes globally through an integrative precision medicine approach. Key to this transformation is the use of systems biology and network medicine, whereby the application of artificial intelligence to "big data", ranging from clinical information to unbiased multiomics (e.g., genomics, transcriptomics, proteomics, and metabolomics) can elucidate disease mechanisms, yield novel biomarkers for disease progression, and identify potential drug targets. In parallel, new computational approaches are helping translate these discoveries into novel therapies and overcome druggability barriers. The transition to a precision-based research and innovation paradigm in cardiovascular medicine will require greater interdisciplinary collaboration, data science implementation at every stage, and new partnerships between academia and industry. Global policy leadership is also essential to implement suitable models of research funding and organization, data infrastructures and policies, medicines regulations, and patient access policies promoting equity.
{"title":"Precision cardiovascular medicine: shifting the innovation paradigm.","authors":"Masanori Aikawa, Abhijeet R Sonawane, Sarvesh Chelvanambi, Takaharu Asano, Arda Halu, Joan T Matamalas, Sasha A Singh, Shizuka Uchida, Elena Aikawa, Alex Arenas, Jean-Luc Balligand, Chiara Giannarelli, Calum A MacRae, Neil V Morgan, Cécile Oury, Hendrik Tevaearai Stahel, Joseph Loscalzo","doi":"10.3389/fsci.2025.1474469","DOIUrl":"10.3389/fsci.2025.1474469","url":null,"abstract":"<p><p>Despite the development of potent drugs for modifiable risk factors and advances in mechanistic biomedical research, cardiovascular diseases (CVDs) collectively remain the leading cause of death globally, indicating a need for new, more effective therapies. A foundational challenge is the multilevel heterogeneity that characterizes CVDs-from their complex pathobiological mechanisms at the molecular and cellular levels, to their clinical presentations and therapeutic responses at the individual and population levels. This variability arises from individuals' unique genomic and exposomic characteristics, underscoring the need for precision approaches. Other key challenges include the long navigation times, high costs, and low success rates for drug development, often compounded by the poor \"druggability\" of new targets. In this article, we explore how these challenges have inspired novel technologies that offer promise in improving health outcomes globally through an integrative precision medicine approach. Key to this transformation is the use of systems biology and network medicine, whereby the application of artificial intelligence to \"big data\", ranging from clinical information to unbiased multiomics (e.g., genomics, transcriptomics, proteomics, and metabolomics) can elucidate disease mechanisms, yield novel biomarkers for disease progression, and identify potential drug targets. In parallel, new computational approaches are helping translate these discoveries into novel therapies and overcome druggability barriers. The transition to a precision-based research and innovation paradigm in cardiovascular medicine will require greater interdisciplinary collaboration, data science implementation at every stage, and new partnerships between academia and industry. Global policy leadership is also essential to implement suitable models of research funding and organization, data infrastructures and policies, medicines regulations, and patient access policies promoting equity.</p>","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-23DOI: 10.3389/fsci.2024.1419497
Luca Perico, Giuseppe Remuzzi
{"title":"COVID-19: the renaissance of science in the face of adversity","authors":"Luca Perico, Giuseppe Remuzzi","doi":"10.3389/fsci.2024.1419497","DOIUrl":"https://doi.org/10.3389/fsci.2024.1419497","url":null,"abstract":"","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"9 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141106869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-23DOI: 10.3389/fsci.2024.1236919
Simon Cauchemez, Giulio Cossu, Nathalie Delzenne, Eran Elinav, Didier Fassin, Alain Fischer, Thomas Hartung, Dipak Kalra, Mihai Netea, Johan Neyts, Rino Rappuoli, Mariagrazia Pizza, Melanie Saville, Pamela Tenaerts, Gerry Wright, Philippe Sansonetti, Michel Goldman
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, and socioeconomic determinants of health throughout life. This article explores how scientists and other stakeholders must collaborate in novel, interdisciplinary ways at these new frontiers of medicine, focusing on communicable diseases, precision/personalized medicine, systems medicine, and data science. The pandemic highlighted the critical protective role of vaccines against current and emerging threats. Radical efficiency gains in vaccine development (through mRNA technologies, public and private investment, and regulatory measures) must be leveraged in the future together with continued innovation in the area of monoclonal antibodies, novel antimicrobials, and multisectoral, international action against communicable diseases. Inter-individual heterogeneity in the pathophysiology of COVID-19 prompted the development of targeted therapeutics. Beyond COVID-19, medicine will become increasingly personalized via advanced omics-based technologies and systems biology—for example targeting the role of the gut microbiome and specific mechanisms underlying immunoinflammatory diseases and genetic conditions. Modeling proved critical to strengthening risk assessment and supporting COVID-19 decision-making. Advanced computational analytics and artificial intelligence (AI) may help integrate epidemic modeling, clinical features, genomics, immune factors, microbiome data, and other anthropometric measures into a “systems medicine” approach. The pandemic also accelerated digital medicine, giving telehealth and digital therapeutics critical roles in health system resilience and patient care. New research methods employed during COVID-19, including decentralized trials, could benefit evidence generation and decision-making more widely. In conclusion, the future of medicine will be shaped by interdisciplinary multistakeholder collaborations that address complex molecular, clinical, and social interrelationships, fostering precision medicine while improving public health. Open science, innovative partnerships, and patient-centricity will be key to success.
{"title":"Standing the test of COVID-19: charting the new frontiers of medicine","authors":"Simon Cauchemez, Giulio Cossu, Nathalie Delzenne, Eran Elinav, Didier Fassin, Alain Fischer, Thomas Hartung, Dipak Kalra, Mihai Netea, Johan Neyts, Rino Rappuoli, Mariagrazia Pizza, Melanie Saville, Pamela Tenaerts, Gerry Wright, Philippe Sansonetti, Michel Goldman","doi":"10.3389/fsci.2024.1236919","DOIUrl":"https://doi.org/10.3389/fsci.2024.1236919","url":null,"abstract":"The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, and socioeconomic determinants of health throughout life. This article explores how scientists and other stakeholders must collaborate in novel, interdisciplinary ways at these new frontiers of medicine, focusing on communicable diseases, precision/personalized medicine, systems medicine, and data science. The pandemic highlighted the critical protective role of vaccines against current and emerging threats. Radical efficiency gains in vaccine development (through mRNA technologies, public and private investment, and regulatory measures) must be leveraged in the future together with continued innovation in the area of monoclonal antibodies, novel antimicrobials, and multisectoral, international action against communicable diseases. Inter-individual heterogeneity in the pathophysiology of COVID-19 prompted the development of targeted therapeutics. Beyond COVID-19, medicine will become increasingly personalized via advanced omics-based technologies and systems biology—for example targeting the role of the gut microbiome and specific mechanisms underlying immunoinflammatory diseases and genetic conditions. Modeling proved critical to strengthening risk assessment and supporting COVID-19 decision-making. Advanced computational analytics and artificial intelligence (AI) may help integrate epidemic modeling, clinical features, genomics, immune factors, microbiome data, and other anthropometric measures into a “systems medicine” approach. The pandemic also accelerated digital medicine, giving telehealth and digital therapeutics critical roles in health system resilience and patient care. New research methods employed during COVID-19, including decentralized trials, could benefit evidence generation and decision-making more widely. In conclusion, the future of medicine will be shaped by interdisciplinary multistakeholder collaborations that address complex molecular, clinical, and social interrelationships, fostering precision medicine while improving public health. Open science, innovative partnerships, and patient-centricity will be key to success.","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"33 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141107897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-23DOI: 10.3389/fsci.2024.1422583
Olusoji Adeyi, Prashant Yadav, Michel Kazatchkine
{"title":"Frontiers of medicine unveiled: equitable access is an imperative","authors":"Olusoji Adeyi, Prashant Yadav, Michel Kazatchkine","doi":"10.3389/fsci.2024.1422583","DOIUrl":"https://doi.org/10.3389/fsci.2024.1422583","url":null,"abstract":"","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"22 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141106512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-25DOI: 10.3389/fsci.2024.1397048
David M. Engelthaler
{"title":"Genomic surveillance and pathogen intelligence","authors":"David M. Engelthaler","doi":"10.3389/fsci.2024.1397048","DOIUrl":"https://doi.org/10.3389/fsci.2024.1397048","url":null,"abstract":"","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"57 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140656556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-25DOI: 10.3389/fsci.2024.1415415
Marion P. G. Koopmans
{"title":"Fast-forwarding collaborative surveillance","authors":"Marion P. G. Koopmans","doi":"10.3389/fsci.2024.1415415","DOIUrl":"https://doi.org/10.3389/fsci.2024.1415415","url":null,"abstract":"","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140654078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-25DOI: 10.3389/fsci.2024.1298248
Marc J. Struelens, Catherine Ludden, Guido Werner, V. Sintchenko, P. Jokelainen, Margaret Ip
This article advocates for mobilizing pathogen genomic surveillance to contain and mitigate health threats from infectious diseases and antimicrobial resistance (AMR), building upon successes achieved by large-scale genome sequencing analysis of SARS-CoV-2 variants in guiding COVID-19 monitoring and public health responses and adopting a One Health approach. Capabilities of laboratory-based surveillance and epidemic alert systems should be enhanced by fostering (i) universal access to real-time whole genome sequence (WGS) data of pathogens to inform clinical practice, infection control, public health policies, and vaccine and antimicrobial drug research and development; (ii) integration of diagnostic microbiology data, data from testing asymptomatic individuals, pathogen sequence data, clinical data, and epidemiological data into surveillance programs; (iii) stronger cross-sectorial collaborations between healthcare, public health, animal health, and environmental surveillance and research using One Health approaches, toward understanding the ecology and transmission pathways of pathogens and AMR across ecosystems; (iv) international collaboration and interconnection of surveillance networks, harmonization of laboratory methods, and standardization of surveillance methods for global reporting, including on pathogen genomic variant or strain nomenclature; (v) responsible data sharing between surveillance networks, databases, and platforms according to FAIR (findability, accessibility, interoperability, and reusability) principles; and (vi) research on genomic surveillance system implementation and its cost-effectiveness for different pathogens and AMR threats across different settings. Regional and global One Health policies and governance initiatives should foster the concerted development and efficient utilization of pathogen genomic surveillance to protect the health of humans, animals, and the environment.
{"title":"Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance","authors":"Marc J. Struelens, Catherine Ludden, Guido Werner, V. Sintchenko, P. Jokelainen, Margaret Ip","doi":"10.3389/fsci.2024.1298248","DOIUrl":"https://doi.org/10.3389/fsci.2024.1298248","url":null,"abstract":"This article advocates for mobilizing pathogen genomic surveillance to contain and mitigate health threats from infectious diseases and antimicrobial resistance (AMR), building upon successes achieved by large-scale genome sequencing analysis of SARS-CoV-2 variants in guiding COVID-19 monitoring and public health responses and adopting a One Health approach. Capabilities of laboratory-based surveillance and epidemic alert systems should be enhanced by fostering (i) universal access to real-time whole genome sequence (WGS) data of pathogens to inform clinical practice, infection control, public health policies, and vaccine and antimicrobial drug research and development; (ii) integration of diagnostic microbiology data, data from testing asymptomatic individuals, pathogen sequence data, clinical data, and epidemiological data into surveillance programs; (iii) stronger cross-sectorial collaborations between healthcare, public health, animal health, and environmental surveillance and research using One Health approaches, toward understanding the ecology and transmission pathways of pathogens and AMR across ecosystems; (iv) international collaboration and interconnection of surveillance networks, harmonization of laboratory methods, and standardization of surveillance methods for global reporting, including on pathogen genomic variant or strain nomenclature; (v) responsible data sharing between surveillance networks, databases, and platforms according to FAIR (findability, accessibility, interoperability, and reusability) principles; and (vi) research on genomic surveillance system implementation and its cost-effectiveness for different pathogens and AMR threats across different settings. Regional and global One Health policies and governance initiatives should foster the concerted development and efficient utilization of pathogen genomic surveillance to protect the health of humans, animals, and the environment.","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"52 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140656493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-04DOI: 10.3389/fsci.2024.1393167
S. Holgate
{"title":"The lived experience of immune-mediated noncommunicable diseases in relation to environmental change","authors":"S. Holgate","doi":"10.3389/fsci.2024.1393167","DOIUrl":"https://doi.org/10.3389/fsci.2024.1393167","url":null,"abstract":"","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"30 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140744991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-04DOI: 10.3389/fsci.2024.1279192
I. Agache, C. Akdis, M. Akdiş, Ali Al-Hemoud, Isabella Annesi-Maesano, John Balmes, Lorenzo Cecchi, Athanasios Damialis, T. Haahtela, Adam L. Haber, Jaime E. Hart, Marek Jutel, Yasutaka Mitamura, B. Mmbaga, Jae-Won Oh, Abbas Ostadtaghizadeh, R. Pawankar, M. Prunicki, Harald Renz, Mary B. Rice, Nelson Augusto Rosario Filho, V. Sampath, C. Skevaki, Francis Thien, C. Traidl‐Hoffmann, G. Wong, Kari C. Nadeau
Global warming and climate change have increased the pollen burden and the frequency and intensity of wildfires, sand and dust storms, thunderstorms, and heatwaves—with concomitant increases in air pollution, heat stress, and flooding. These environmental stressors alter the human exposome and trigger complex immune responses. In parallel, pollutants, allergens, and other environmental factors increase the risks of skin and mucosal barrier disruption and microbial dysbiosis, while a loss of biodiversity and reduced exposure to microbial diversity impairs tolerogenic immune development. The resulting immune dysregulation is contributing to an increase in immune-mediated diseases such as asthma and other allergic diseases, autoimmune diseases, and cancer. It is now abundantly clear that multisectoral, multidisciplinary, and transborder efforts based on Planetary Health and One Health approaches (which consider the dependence of human health on the environment and natural ecosystems) are urgently needed to adapt to and mitigate the effects of climate change. Key actions include reducing emissions and improving air quality (through reduced fossil fuel use), providing safe housing (e.g., improving weatherization), improving diets (i.e., quality and diversity) and agricultural practices, and increasing environmental biodiversity and green spaces. There is also a pressing need for collaborative, multidisciplinary research to better understand the pathophysiology of immune diseases in the context of climate change. New data science techniques, biomarkers, and economic models should be used to measure the impact of climate change on immune health and disease, to inform mitigation and adaptation efforts, and to evaluate their effectiveness. Justice, equity, diversity, and inclusion (JEDI) considerations should be integral to these efforts to address disparities in the impact of climate change.
{"title":"Immune-mediated disease caused by climate change-associated environmental hazards: mitigation and adaptation","authors":"I. Agache, C. Akdis, M. Akdiş, Ali Al-Hemoud, Isabella Annesi-Maesano, John Balmes, Lorenzo Cecchi, Athanasios Damialis, T. Haahtela, Adam L. Haber, Jaime E. Hart, Marek Jutel, Yasutaka Mitamura, B. Mmbaga, Jae-Won Oh, Abbas Ostadtaghizadeh, R. Pawankar, M. Prunicki, Harald Renz, Mary B. Rice, Nelson Augusto Rosario Filho, V. Sampath, C. Skevaki, Francis Thien, C. Traidl‐Hoffmann, G. Wong, Kari C. Nadeau","doi":"10.3389/fsci.2024.1279192","DOIUrl":"https://doi.org/10.3389/fsci.2024.1279192","url":null,"abstract":"Global warming and climate change have increased the pollen burden and the frequency and intensity of wildfires, sand and dust storms, thunderstorms, and heatwaves—with concomitant increases in air pollution, heat stress, and flooding. These environmental stressors alter the human exposome and trigger complex immune responses. In parallel, pollutants, allergens, and other environmental factors increase the risks of skin and mucosal barrier disruption and microbial dysbiosis, while a loss of biodiversity and reduced exposure to microbial diversity impairs tolerogenic immune development. The resulting immune dysregulation is contributing to an increase in immune-mediated diseases such as asthma and other allergic diseases, autoimmune diseases, and cancer. It is now abundantly clear that multisectoral, multidisciplinary, and transborder efforts based on Planetary Health and One Health approaches (which consider the dependence of human health on the environment and natural ecosystems) are urgently needed to adapt to and mitigate the effects of climate change. Key actions include reducing emissions and improving air quality (through reduced fossil fuel use), providing safe housing (e.g., improving weatherization), improving diets (i.e., quality and diversity) and agricultural practices, and increasing environmental biodiversity and green spaces. There is also a pressing need for collaborative, multidisciplinary research to better understand the pathophysiology of immune diseases in the context of climate change. New data science techniques, biomarkers, and economic models should be used to measure the impact of climate change on immune health and disease, to inform mitigation and adaptation efforts, and to evaluate their effectiveness. Justice, equity, diversity, and inclusion (JEDI) considerations should be integral to these efforts to address disparities in the impact of climate change.","PeriodicalId":101325,"journal":{"name":"Frontiers in science","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140744692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：